This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Feb;19(2):457-8.

doi: 10.1097/MIB.0b013e318280fcf5.

Rifaximin in IBD: is it time to beat back the bugs as induction therapy in Crohn's disease?

Affiliations

PMID: 23314246
DOI: 10.1097/MIB.0b013e318280fcf5

Comment

Rifaximin in IBD: is it time to beat back the bugs as induction therapy in Crohn's disease?

Kim L Isaacs. Inflamm Bowel Dis. 2013 Feb.

. 2013 Feb;19(2):457-8.

doi: 10.1097/MIB.0b013e318280fcf5.

Author

Affiliation

¹ University of North Carolina Gastroenterology and Hepatology Chapel Hill, NC, USA.

PMID: 23314246
DOI: 10.1097/MIB.0b013e318280fcf5

No abstract available

PubMed Disclaimer

Comment on

Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease.
Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P; Retic Study Group (Rifaximin-Eir Treatment in Crohn's Disease). Prantera C, et al. Gastroenterology. 2012 Mar;142(3):473-481.e4. doi: 10.1053/j.gastro.2011.11.032. Epub 2011 Dec 6. Gastroenterology. 2012. PMID: 22155172 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations